PA
ALLT icon

PharVision Advisers’s Allot ALLT Stock Holding History

PharVision Advisers’s Portfolio ALLT Stock Details ALLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,604
Closed -$350K – 117
2025
Q4 		$350K Buy
35,604
+15,417
+76% +$148K 0.18% 192
2025
Q3 		$214K Buy
+20,187
New +$171K 0.12% 461

Other funds holding ALLT

LLL
Lynrock Lake LP Rye Brook, New York $1.46B AUM 17.55% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $406M AUM 164.47% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

PharVision Advisers's ALLT Position: Q1 2026 in Review

PharVision Advisers sold out of Allot (ALLT) in Q1 2026, closing a stake of 35,604 shares — an estimated $350K sold.

PharVision Advisers first reported a position in ALLT in Q3 2025 and held it in 2 quarters. The position peaked at $350K in Q4 2025. 79 funds tracked by Wall St. Rank hold ALLT as of Q1 2026.

  • PharVision Advisers reported no remaining Allot position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 35,604 Allot shares in Q1 2026, an estimated $350K.
  • PharVision Advisers first reported a position in Allot in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's Allot position peaked at $350K in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Allot as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.